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Abstract The deep waters surrounding the coastline
of the northern parts of Norway represent an exciting
biotope for marine exploration. Dark and cold Arctic
water generates a hostile environment where the
ability to adapt is crucial to survival. These waters
are nonetheless bountiful and a diverse plethora of
marine organisms thrive in these extreme conditions,
many with the help of specialised chemical com-
pounds. In comparison to warmer, perhaps more
inviting shallower tropical waters, the Arctic region
has not been as thoroughly investigated. MabCent is a
Norwegian initiative based in Tromsø that aims to
change this. Since 2007, scientists within MabCent
have focussed their efforts on the study of marine
organisms inhabiting the Arctic waters with the long
term goal of novel drug discovery and development.
The activities of MabCent are diverse and range from
sampling the Arctic ice shelf to the chemical synthesis
of promising secondary metabolites discovered during
the screening process. The current review will present
the MabCent pipeline from isolation to identification
of new bioactive marine compounds via an exten-
sive screening process. An overview of the main
activities will be given with particular focus on
isolation strategies, bioactivity screening and structure
determination. Pitfalls, hard earned lessons and the
results so far are also discussed.
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Introduction
With one of the longest coastlines in the world it is not
surprising that Norway is a country with a rich history
in both marine exploration and exploitation. The
discovery of massive oil and gas deposits in the late
1960s had a huge impact, rapidly transforming a
humble nation dependent on fishing and shipping to a
very wealthy country. The initial discoveries were
made in the North Sea and have been followed by
significant finds in the Barents Sea making Norway a
developed country with a high standard of living.
Being well aware of the fact that a national economy
based on the petroleum industry is not long term viable
the government is now attempting to convert some of
its revenue into sustainable industries capable of
excelling in the post-petroleum era. As a result, several
initiatives to generate internationally competitive
Centres for Research based Innovation (CRI) have
been launched by the Norwegian research council
since 2007. Furthermore, in 2009, the Norwegian
government launched a national strategy entitled
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‘‘Marine bioprospecting—a source of new and viable
wealth creation’’, providing funding for a national
infrastructure and research within marine natural
products and drug discovery.
Norwegian scientists are for this reason once more
turning to the ocean for inspiration. The deep fjords
and the open oceans surrounding the Norwegian
mainland are cold and dark and organisms willing to
survive here must adapt to the extreme conditions.
They do so by producing a range of secondary
metabolites and specialised proteins providing them
with advantages and protection against predation and
microbial intruders (Kubanek et al. 2003; Matz et al.
2008). Such compounds have been chemically opti-
mised during millions of years of evolution and
represent entities with significant potential for several
industrial and medical applications (Molinski et al.
2009; Mayer et al. 2010). Nearly two thirds of the
commercial pharmaceuticals originate from natural
products (Cragg et al. 2009). There is a precedence for
marine metabolites as approved therapeutics. Zicon-
otide (Prialt) is a synthetic analogue of a naturally
occurring 25-amino acid peptide, x-Conotoxin
MVIIA, which is isolated from the venom of the
piscivorous cone snail Conus magus (Olivera et al.
1985; Terlau and Olivera 2004). It was the first
marine-derived compound approved by FDA in
December 2004 as a potent analgesic (Garber 2005).
Several other promising leads such as bryostatin-1
(compound 1 in Fig. 1) from Bugula neritina (Pettit
et al. 1982) with subnanomolar binding to protein
kinase C as well as numerous other biological
activities (Mutter and Wills 2000) and salinospora-
mide A, active against multiple myeloma (Chauhan
et al. 2008; Fenical et al. 2009), shown as compound 2
in Fig. 1 are currently under development.
As of 2011, six marine derived drugs have been
approved by FDA and one by the European Union.
Thirteen others are in various stages of clinical trials
(Mayer et al. 2010, 2011).
Despite its abundance of marine organisms, Nor-
way has done relatively little towards studying their
contents. MabCent is a Norwegian initiative headed by
Professor Trond Ø. Jørgensen based in Tromsø that
aims to change this. The centre for research based
innovation has been focussed on studying Arctic
marine organisms as these represent a group of
organisms that have not been well studied and have
the potential to display interesting biochemistries due
their adaption to living conditions near, and below the
freezing point of water (Fig. 2).
Easy access to organisms is a significant advantage
and it is not coincidental that the MabCent endeavour
is based at the University of Tromsø (UiT), the
northernmost university in the world at 70 north,
some 300 km north of the Arctic Circle. UiT was
particularly well suited for this task with all the
essential competence and infrastructure (ranging from
Arctic research vessels and marine biologist to struc-
tural chemists) readily available. With a gross budget
of nearly 23 million Euros from the Norwegian
research council over a period of 8 years and





lactone bryostatin-1 (1) with
its 11 stereocentres was only
recently prepared
synthetically (Keck et al.
2011). The unusual b-
lactone salinosporamide A
isolated from the halophilic
actinomycete Salinispora
(2) is a potent orally active
proteasome inhibitor
(Chauhan et al. 2005)
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additional financial support from UiT and commercial
partners the project management have sufficient
funding and time to serve its main purpose: ‘‘to find
and develop high-value bioactive products for scien-
tific and commercial exploitation by screening com-
pounds from Arctic organisms’’. All the activities are
based in Tromsø but there is also collaboration with
the newly established Marine Biodiscovery Centre in
Aberdeen, Scotland.
Nearly sixty staff members are associated with the
MabCent activities and the centre has its own Ph.D.
programme and an external scientific advisory board.
In addition, four commercial partners are also partic-
ipating in the research (Table 1). These partners
contribute both financially and scientifically by pro-
viding key competences within their specialised field
of expertise. For an annual fee the companies have the
right to develop promising leads into commercial
products according to a first right of refusal agreement.
Four platforms manage the main activities and their
responsibilities are listed in Table 1.
Collection
The availability of biological material is paramount,
and the cooperation with the marine biobank Marbank
is therefore essential. Marbank has the national
responsibility for the collection and preservation of
marine resources/organisms for scientific research,
commercial opportunities and exploitation purposes.
Three research vessels are at Marbank’s disposal and
they are purposefully designed for the task. The largest
one, Helmer Hanssen, at 60 m is a modern science
platform capable of long journeys into the pack ice and
capable of collecting samples in several thousand
metres of water (Fig. 3). While most of the ocean
waters on the globe can be regarded as dark and cold
and therefore potentially rich in psychrophilic organ-
isms, MabCent has mainly focused on Arctic waters
with temperatures near or below zero degrees. The
sampling stretches from the pack ice north of
Svalbard, to the northern Norwegian coast line. Sub-
zero degree water temperatures can also be found in
deep water pockets in several of the fjords along the
northern coastline. The material is collected during
many annual excursions.
Several types of techniques are used for sample
collections. Marine bacteria and microalgae are col-
lected from both sediment and water samples using
grabs and a CTD-rosette array offering enormous
potential for biodiversity (Imhoff et al. 2011; Gulder










Marbio Screening and Purification
NorStruct Structure elucidation macromolecules
SmallStruct Structure elucidation small molecules
Fig. 2 The deep cold waters are rich in biodiversity and shown
are three examples of diverse and colourful inhabitants. From
the left Parastichopus tremulus, Hormathia nodosa and the
amphipode Epimeria loricata to the right. Johan Svenson &
Robert Johansen, UiT/Marbank
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and Moore 2009). The ability of marine bacteria to
produce bioactive compounds has been recognised for
more than 60 years (Rosenfeld and ZoBell 1947) and
the first isolation of an antimicrobial compound (a
pyrrole antibiotic, 2-(3,5-dibromophenyl)-3,4,5-trib-
romopyrrole) from a marine bacteria was reported
in 1966 (Burkholder et al. 1966). As most marine
organisms contain both exo- and endobiotic microor-
ganisms it is generally difficult to establish the
biosynthetic source of many marine natural products
(König et al. 2006). There is growing evidence that the
accompanying microflora is responsible for substan-
tial amounts of the secondary metabolites discovered
(Imhoff et al. 2011; Sudek et al. 2007). The Arctic
marine bacteria have proven to be generally difficult to
cultivate and only a minority can be grown on standard
media in analogy to other marine bacteria (Jensen and
Fenical 1994). Metagenomics can nevertheless be
successfully applied to extract genetic information
about promising cold-adapted proteins and secondary
metabolites independent of cultivation (Simon and
Daniel 2011; Godzik 2011; Kennedy et al. 2010;
Sudek et al. 2007). Bottom-dwelling benthic organ-
isms are collected through diving or several types of
trawls. Each species is taxonomically identified and
sufficient material is collected. Microbiological and
genetic material from each species is also stored.
Those microalgae and bacteria that can be cultivated
are grown in the lab to provide enough biomass for
isolation of secondary metabolites. This is the most
sustainable way to get access to biological material but
the generality is hampered by several factors discussed
later (Fig. 4).
Purification and screening
Once the biological sample has been gathered and
sorted it needs to be analysed and that is the task of
Marbio. Marbio is a high-throughput analytical
laboratory with access to a range of automated and
manual chromatographic and spectroscopic tools as
well as a range of biochemical and cellular assays.
Marine metabolites can be fractionated and identified
and their discrete bioactivities evaluated. Before the
bioactivities can be studied, the organism is lyophi-
lised and extracted to yield an aqueous and organic
(dichloromethane:methanol) extract. At least 200 g of
Fig. 3 Access to sturdy and modern research vessels with ice
breaking capacity enables sampling in the extreme environ-
ments studied. Shown above is the 60 metre Helmer Hanssen
(previously known as Jan Mayen) on a collection cruise in
hostile surroundings.  TUNU-MAFIG, UiT
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biological material is used in an attempt to generate
enough pure compounds to allow for spectroscopic
structural elucidation. Both the organic and aqueous
fractions are analysed. Each extract is separated on a
flash chromatography system packed with HP20. 1 g
of dried extract is dry loaded and eluted at a high flow
(10–12 mL/min) using a gradient of water, methanol
and acetone and fractionated into eight fractions.
The fractions are screened in several biochemical
and cellular assays shown in Table 2. Only those
displaying genuine dose–response behaviour upon
dilution are further considered. The assays used are
based on the needs of the commercial partners and on
their clinical relevance. Major disease states such as
cancer, infection, life-style diseases such as obesity,
metabolic syndrome, and type-II diabetes are therefore
targeted in addition to a more general search for
antioxidants and immunomodulating compounds.
Positive fractions (Fig. 5) are further purified by
subsequent RP-HPLC separation steps to reduce the
complexity of the active fraction and to pin the
bioactivity to a single fraction. Once that has been
achieved the task of identification ensues. While the
strategy of MabCent is to look at marine organisms
found in the Arctic, several of these have wider
distributions. Consequently, most of the hits observed
in the primary screening are caused by secondary
metabolites that already have been discovered and
described. Such a needle in the haystack challenge is
only to be expected and identifying these known
compounds as early as possible and removing them
from biodiscovery pipeline is crucial. This dereplica-
tion process is on-going from the stage where the
activity has been narrowed down to a single fraction.
High resolution mass spectrometry (HR-MS) anal-
ysis provides the first indication of novelty of the
active compounds. The elemental composition, cal-
culated from the accurate mass and the isotopic
distribution is used to search databases such as the
Dictionary of Marine Natural Products and AntiMarin
before an isolation is attempted. By relying mainly on
MS for the dereplication, significant time is saved as it
does not require pure fractions or isolated compounds.
Structural suggestions can to some extent be verified
Fig. 4 DNA is collected from each collected species, both microorganisms and benthic. Shown to the right are Munida sarsi lobsters
and Porosia glacialis microalgae. Johan Svenson & Hans Christian Eilertsen, UiT
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using MSn-fractionation experiments. Seemingly
novel compounds are transferred to the structure
determination platforms.
Structure determination
The two platforms devoted to structure determination
are in charge of the final structural trials. Macromol-
ecules are handled by the Norwegian centre of
structural biology (NorStruct) with particular experi-
ence and expertise in handling cold-adapted proteins.
Cold adaption is crucial for survival at very low
temperatures and is characterised by an increased
molecular flexibility to compensate for the low
surrounding temperatures. Such flexibility lead to an
increased catalytic efficiency and a lower thermal
stability (Smalas et al. 2000). Those traits permit the
cold adapted enzymes to operate efficiently at low
temperatures and it also allows for a simple way of
controlling their activity, making them particularly
interesting for molecular biology and biotechnological
applications. X-ray crystallography is routinely used
in conjunction with computational chemistry to study
the proteins. NorStruct have characterised and studied
several novel cold adapted enzymes, some of which
have been transformed into commercial biotechno-
logical and molecular biology products such as uracil-
DNA glycosylase from Atlantic cod (Gadus morhua)
(Leiros et al. 2003) and heat-labile shrimp alkaline
phosphatase from Pandalus borealis (de Backer et al.
2002).
Smaller, more drug-like secondary metabolites that
are suited for NMR analysis represent the task of
SmallStruct. Access to cryoprobe fitted NMR-equip-
ment enables analysis of the generally small sample
amounts resulting from the purification and isolation
processes. While the atomic connectivity of an
unknown molecule is relatively easy to establish with
NMR, the three-dimensional shape presents more of a
problem. The low amount of pure compound often
prevents the formation of crystals for X-ray analysis.
Theoretical approaches in conjunction with chiropti-
cal spectroscopic techniques, such as Raman optical
activity, vibrational circular dichroism and electronic
circular dichroism are therefore under development
together with the Norwegian centre of theoretical and
computational chemistry. This allows in-solution
determination of absolute configuration in cases where
X-ray analysis is not a feasible option. This approach
was recently employed to the synoxazolidinones to
reveal their absolute configuration (Hopmann et al.
2012). SmallStruct is further involved in the synthetic
aspects of MabCent and are performing analogue
synthesis and development of the most interesting
leads. The group has particular experience from the
field of naturally occurring bioactive peptides and
peptidomimetics (Svenson et al. 2008; Karstad et al.
2010; Flaten et al. 2011).
Hits so far
So far more than 25,000 fractions from 140 different
marine organisms (mostly benthic) have been ana-
lysed and numerous bioactive marine compounds have
been isolated and characterised. A schematic repre-
sentation of the distribution and origin of the analysed
organisms is shown in Fig. 6.
The vast majority of the compounds isolated are
however already known ones and represent derepli-
cation rather than pure discoveries as the majority of
the species studied and their accompanying microflora
have a large geographical distribution. Of the novel
Table 2 MabCent screening targets
Activity Target Type
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compounds discovered, the antibacterial, antifungal
and cytotoxic synoxazolidinone (Tadesse et al. 2010;
Tadesse et al. 2011a) family stands out (Fig. 7) and
they are being further developed by the commercial
partner Lytix Biopharma AS.
This is a family of closely structurally related
compounds that was initially isolated in surprisingly
high concentrations from the sub-Arctic ascidian
Synocium pulmonaria. The synoxazolidinones contain
a highly unusual heterocyclic oxazolidinone core
linking two amino acid (Arg and Tyr) derivatives
together. They represent only the second report of a
naturally occurring 4-oxazolidinone motif with the
highly antibacterial lipoxazolidinone family being the
first one (Macherla et al. 2007) reported. The motif is
also shared with the novel synthetic 50S ribosomal
subunit binder antibiotic linezolid (Moellering 2003).
It has not been established whether the biosynthetic
origin of the synoxazolidinones is the ascidian itself or
symbiotic microorganisms. Such brominated dipepti-
dic derivatives are regularly produced by marine
organisms and the synoxazolidinones share structural
traits with for example barettin (Lidgren and Bohlin
1986) from the cold-water sponge Geodia baretti and
ianthelline (Litaudon and Guyot 1986) found in the
tropical Ianthella ardis as shown in Fig. 8.
In addition, the several recently described new
members of the antibacterial eusynstyelamide family
also share this structural composition of halogenated
hydrophobic bulk and one or two cationic groups
(Tadesse et al. 2011b). A clear correlation between
bioactivities and the nature of the cationic side chains
Fig. 6 Pie chart diagram over the distribution of the organisms
screened by Marbio. The majority of the organisms are of
benthic origin with microalgae, diatoms (Bacillariophyta) being
the only class of microorganisms screened so far
Fig. 5 Antibacterial screening of 40 fractions from a RP-HPLC purification of a marine sample extract. High activity against both
Gram positive and Gram negative bacteria is observed in fractions 10–14
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were seen for these novel compounds (Tadesse et al.
2011b). Currently, numerous novel bioactive com-
pounds are undergoing structural elucidation and the
annual number is expected to increase the coming years
due to the improved efficiency of Marbio and the
introduction of both bacteria and on-site grown micro-
algae into the screening process. Nearly 1500 isolates
of microorganisms have been collected and 16S
sequenced and they have yet to enter the pipeline
which has so far been nearly exclusive for benthic
organisms with the exception of the microalgae. The
bulk of the microorganisms belong to the Proteobac-
teria and Bacteriodetes phyla as shown in Fig. 9. The
collected microorganisms have further been taxonom-
ically divided into 500 species and 70 different families.
Discussion
MabCent has been up and running since 2007 and will
continue at least until the end of 2014 in its current
form. Despite the fact the project is now on its fifth
year there are still activities that can be improved and
the learning curve for most involved staff has been
steep and several lessons have been learnt the hard
way. Initially, the progress was hindered by idiosyn-
cratic false positives and active fractions without any
apparent content. A change from an initial 40 fraction
HPLC fractionation to an early flash chromatographic
separation and a proper dose–response analysis of the
active hits reduced those numbers to satisfactory
levels.
Fig. 8 Many marine
secondary metabolites are
derived from heavily post-
translationally modified
dipeptides and several such
compounds have been
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One of the most challenging issues is, despite the
geographical placement of MabCent, access to suffi-
cient amount of biological material and subsequently
pure compounds. This is a universal challenge for any
marine bioprospecting endeavour, perhaps best illus-
trated by the 18 grams of bryostatin-1 needed for
preclinical and clinical studies in 1991 which was
isolated from approximately 12.6 metric tonnes of wet
organism over a period of 10 months (Schaufelberger
et al. 1991). Multi tonne amounts were also needed for
the isolation of sufficient material of halichondrin
(Hirata and Uemura 1986) and the approved antitu-
moral ecteinascidin 743 (Trabectidin/Yondelis)
which had its final structural elucidation delayed by
two decades due to insufficient amounts (Molinski
et al. 2009). A low amount of starting material is thus
an undisputed way to miss out on the most active
compounds as they are by definition not needed in the
same amounts as other metabolites. The antimitotic
macrolide halistatin-1 for example is only present at
8.8 parts per billion in the organism (Pettit et al. 1993)
illustrating that attention to the ‘‘small peaks’’ can be
crucial. This has been obvious several times in the
MabCent screening where seemingly empty HPLC
fractions generate positive results in the screening
assays. MS-analysis sometimes later reveals the
presence of potentially novel compounds in the
fractions but in no-way near high enough amounts
for characterisation. The 200 grams of organism
generally used by MabCent for the initial extraction
may appear insufficient, but already at this stage, that
minimum amount prevents analysis of numerous
collected organisms. Those highly active compounds
can also cause initially perplexing results upon
purification of active fractions of seemingly high
molecular content. For example: A 1 nM agonist
present at a 1 % concentration in a mixture with 99 %
of another inactive compound will provide the mixture
with a promising IC50 of 0.1 lM. The agonist itself
will nevertheless most likely be regarded as noise or as
‘‘an acceptable amount’’ of contamination in the initial
NMR analysis of the major inactive compound in that
mixture thought to generate the bioactivity. Further
purification removing the actual agonist will yield a
pure major product with no bioactivity whatsoever in
the final dose–response analysis. Such scenarios are
particularly prone to appear when working with
automated high-throughput techniques.
Only the most common benthic organisms and
macroalgae are readily available on demand and these
are also frequently the species already most thoroughly
studied by others. Gathering Arctic organisms far out
at sea in a dark, cold and hostile environment is not for
the faint hearted and is not to be compared with a reef
walk collection at low tide on a tropical coral reef. For
this reason it is difficult to resample an already visited
location to stock up on more of the organism if the
initial results are encouraging and more material
required. Seasonal variation also influences the pro-
duction of secondary metabolites and it has been
shown that the same species collected at the identical
location a year later does not necessarily contain the
same compounds (Molinski et al. 2009; Tadesse et al.
2010). So in short, one must make sure to collect as
much as possible while sampling and only allow the
freezer capacity on the vessel to be the limiting factor.
Such an approach raises questions about sustainability
(Bohlin et al. 2010) and it is clear that Nature will, only
as an exception, be able to provide enough material
once a commercially viable compound has been
identified. If the producing organism cannot be aquaf-
armed, or if the compound itself cannot be synthesised,
or produced by microorganisms on a large scale then
one is faced with plummeting odds for success after the
initial discovery.
Aware of these hurdles, MabCent has dedicated
significant resources into the development of methods
to grow microalgae on a large scale. The experiments
have so far been successful and several species of
diatoms can now be readily grown in 600 L incubators
in high concentrations as shown in Fig. 10.
Screening of these organisms has just begun and it
is realistic to expect that this strategy will generate
Fig. 9 Pie chart diagram of the phyla distribution of the
microorganisms collected by Marbank
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rapid access to a renewable source of biological
material. Extra attention to growth conditions must
nevertheless be paid as most of the secondary metab-
olites serve as defence mediators and their production
may be lowered or stopped when grown in a mono-
culture without competing species or predators pro-
viding a selection pressure. This has previously been
shown for the alga Phaeocystis pouchetii, that only
upon grazing releases toxic aldehydes to fend off the
intruders (Hansen et al. 2004). The ‘‘suicide’’ defence
mechanism, triggered by being consumed, of the
diatom Thalassiosira rotula is another example
(Pohnert 2002) illustrating that carefully combined
cultures may be needed to generate biomass that is also
containing the desired compounds. The off-shore
harvest and large scale in-shore aquaculture of the
sponge Lissodendoryx n. sp. to eventually produce
310 mg of halichondrin B illustrate that with sufficient
financial support it may also be possible grow relevant
marine macroorganisms (Munro et al. 1999; Molinski
et al. 2009).
Most of the MabCent pipeline is designed for high-
throughput and automation (Luesch 2006). This
generally works satisfactory for the assays but is less
effective for the fractionation process. The challenges
associated with high-throughput and natural product
extracts are established and several technological
improvements are under development (Koehn and
Carter 2005). The purification has benefited from
applying extra manual manpower and attention to this
stage of the process. Ideally each fraction should be
followed by a single scientist but that is not a realistic
approach given the number of species collected and
the timeframes of the project. MabCent is funded for
8 years and its ambition is to screen as many Arctic
marine organisms as possible within that period. Such
ambitions can only be achieved using a certain degree
of high-throughput and automation and it may also
potentially mean that some of the low concentration/
high affinity compounds could pass through the
system without the attention they need to be discov-
ered. All the data from the screens are however stored
and extracts with high potencies but no or low
apparent content can be backtracked and re-analysed
later once the ‘‘lowest hanging fruits’’ have been
studied.
Fig. 10 Focus on organisms that can be grown in a controlled
fashion is of high priority for both sustainability and practical
reasons. Diatoms can for example be readily produced in both
bags (left) or large scale cylinder incubators (right). Arctic
microalgae are flexible and high producing at low light,
temperature and nutrition (N&P). Hans Christian Eilertsen &
Richard Ingebrigtsen UiT
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Outlook
The MabCent project has now passed halfway and the
results of the final 3 years will most likely influence
the future direction of research within this field in
Norway. The MabCent operation has survived the first
difficult years and is now running smoothly and
productively and the expectations remain high. With
the microorganisms now entering the screening stage
there is a general belief that the number of novel
compounds will increase.
Several groups at other Norwegian universities
have independently started to look into marine
bioprospecting and marine chemistry but they are still
in the initial start-up phases. Norway is a small country
and a national strategy has been developed to generate
synergies and make the most of the national resources
and competences to allow for future focus on this field.
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